| INTRODUCTION
Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease, affecting around 170 million persons or 3% among total population worldwide. Anti-HCV assays are widely used as a screening tool for HCV infection. As a rule, screening tests for the diagnosis of infectious diseases need to have high sensitivities to detect all or nearly all of true-positive cases. As a consequence, screening tests generally produce more false-positive results than confirmatory tests, but this sacrifice of specificity would be tolerated when a good confirmatory test is available and the consequences of the false-positive results are also be tolerable. In these circumstances, the recombinant immunoblot assay (RIBA) had been widely used as a confirmatory tool for anti-HCV positive cases owing to its high specificity, 3, 4 although this assay is labor-intensive and time-consuming. However, reactive results from an anti-HCV assay cannot discriminate persons with resolved past HCV infection from those who are currently infected with HCV.
The United States Centers for Disease Control and Prevention (CDC) had recommended that an individual would be considered to have serologic evidence of HCV infection only after a positive result of anti-HCV has been confirmed by RIBA or HCV RNA PCR, particularly in populations with a lower prevalence of disease, to verify false-positive screening test results. 3 However, the majority of laboratories report positive anti-HCV results based on a positive screening assay alone.
The testing algorithm includes an option for using the signal-to-cut-off ratio (S/CO) of a positive result from an anti-HCV assay as a screening test. This can be an alternative to RIBA or PCR in some instances, reducing the necessity for supplemental testing and providing additional clue on the subject's true anti-HCV antibody status.
In 2013, CDC published an updated guidance for clinicians and laboratorians on testing for HCV infection. 5 In this guideline, a single nonreactive anti-HCV result indicates no HCV antibody detected, and a reactive result imply current HCV infection, or resolved past HCV infection, or false-positivity. In addition, a reactive result is recommended to be followed by HCV RNA PCR but not by RIBA owing to the discontinuation of widely used RIBA HCV. Consequently, high specificity as well as high sensitivity of an anti-HCV assay became more important. To trade-off sensitivity of an assay against specificity, appropriate cut-off for the determination of results would be needed since low cut-off can guarantee higher sensitivity while the specificity would be sacrificed.
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Regardless of the anti-HCV prevalence or characteristics of the tested population, a specific S/CO can be used to predict a true anti-HCV-positive result determined by supplemental tests such as RIBA for ≥95% of the time. 3 For instance, the S/CO predictive of a true-positive ≥95% of the time for the Vitros Anti-HCV assay was sug- 
| MATERIALS AND METHODS

| Subjects and case definition
Between January 2013 and December 2015, a total of 41 694 cases excluding duplicated patients were tested in a single general hospital by using the Elecsys Anti-HCV II assay (Roche Diagnostics GmbH, Mannheim, Germany). As a policy of our laboratory on routine testing for anti-HCV, samples showing initial S/CO equal to or greater than 0.80 were retested when there was neither obvious history of HCV infection nor previous results for laboratory tests such as anti-HCV, RIBA, and HCV RNA PCR.
For this study, medical records for the subjects including previous and follow-up laboratory tests regarding HCV infection were retrospectively reviewed in duplicates by two or more physicians independently to determine each case as one with or without HCV infection, when the initial S/CO by the Elecsys assay was above 0.80.
When accorded with one of the following criteria, the case was defined as "true HCV infection" which includes current HCV infection or resolved past HCV infection:
1. The follow-up (within 3 months) and/or previous anti-HCV were consistently positive more than once.
2.
One or more of the results among follow-up (within 3 months) or previous tests including RIBA and HCV RNA PCR were positive.
3.
The patient had obvious history of HCV infection in the medical records and showed one or more positive results for follow-up (within 3 months) or previous laboratory tests including anti-HCV, RIBA, and HCV RNA PCR.
The case was defined as "no evidence of HCV infection" when the subjects corresponded to one of the following criteria:
1. The initial result by the Elecsys Anti-HCV II assay was negative, and the patient showed normal aminotransferase levels, and he/she already had negative previous results for anti-HCV or had no history of HCV infection in the medical records.
When the initial and repeated results of the Elecsys Anti-HCV
assay were discrepant but the aminotransferase levels of the patient were within normal, and he/she had no history of HCV infection and one or more of the results from previous or follow-up anti-HCV and/or RIBA were all negative.
When a case was not able to be classified as either "true HCV infection" or "no evidence of HCV infection," the subject was assorted as the group with unclear history of HCV infection and excluded from further analysis.
This study was approved by the Institutional Review Board of Ilsan
Hospital.
| Assays
Anti-HCV was detected by using cobas e 601 analyzer with the Elecsys Anti-HCV II assay kit (Roche Diagnostics GmbH). This assay utilizes the electrochemiluminescence immunoassay (ECLIA) princi-
ple. An S/CO equal to or greater than 1.00 is suggested to be positive for anti-HCV by the manufacturer. In this study, cases with initial Receiver operating characteristics curve analysis was performed to calculate the area under the curve (AUROC) of the Elecsys assay for predicting "true HCV infection." The optimal S/CO was defined as 
| RESULTS
| Distribution of the S/COs
The initial S/COs by the Elecsys Anti-HCV II assay are summarized in the Meanwhile, the median S/CO of the 62 cases with unclear history of HCV infection was 24.6 (1st to 3rd quartiles=7.9-47.5). Excluding those, a total of 41 632 cases were divided into 430 subjects with "true HCV infection" and 41 202 with "no evidence of HCV infection" (Table 2) . Median S/COs by the Elecsys assay were 41.9 (1st to 3rd quartiles=24.9-69.8) for the "true HCV infection" group and 0.05 (1st to 3rd quartiles=0.04-0.08) for the "no evidence of HCV infection" group ( Figure 1 ).
| Diagnostic performances of the Elecsys Anti-HCV II assay
Excluding 62 cases with unclear HCV infection history, 99.85% among the 41 632 initial results by the Elecsys Anti-HCV II assay were concordant with the diagnosis on HCV infection (Table 2) . Sensitivity, specificity, PPV, and NPV of the Elecsys assay were respectively 99.30%, 99.86%, 88.04%, and 99.99%, where the prevalence of the HCV infection was 1.0% (Table 3 ).
In addition, the AUROC of the Elecsys assay for detecting "true HCV infection" cases was 0.9980 (95% CI=0.9944 to 1.0017), and the optimal S/CO cut-off showing maximum diagnostic performances was 0.93 with sensitivity of 99.53% and specificity of 99.85%.
| Comparison of the Elecsys Anti-HCV II assay and RIBA
A total of 97 cases were confirmed by the RIBA. Of these cases, Table 4 . The prevalence of HCV infection was 1.0%.
| Correlation between the results of anti-HCV assay and HCV RNA PCR
to 3rd quartiles=28.7-67.0) for the HCV RNA-positive cases and 22.5 (1st to 3rd quartiles=2.2-57.2) for the HCV RNA negative cases, and they were statistically significant (P<.0001).
| The S/CO for predictive of a true positive
Results of the probit analysis are summarized in the Table 5 and Meanwhile, the prevalence of anti-HCV in our data was 1.0%, and similar to this, the prevalence of HCV infection in Korea was reported to be 0.78%. 13 In this situation of relatively low prevalence, PPV of an anti-HCV assay as a screening tool would be not high owing to false-positive results. Actually, PPV of the Elecsys Anti-HCV II assay in our results was 88.04%, even though the sensitivity and specificity of the assay were 99.30% and 99.86% respectively. Similarly, PPV of the same assay in a recent study was 85.71% where the prevalence of anti-HCV was 2.1%, although only 18 true-positive cases were included in the evaluation. 14 Reagents for RIBA are now discontinuing and unavailable, and the procedure of RIBA is labor-intensive and time-consuming. Therefore, clinical laboratories would need to apply their own algorithms without using RIBA to confirm the positive results of an anti-HCV assay. Although we used patients' medical records and laboratory results including RIBA and HCV RNA assay as a source to determine true anti-HCV status, we utilized data from large population to enhance the validity of study results. With the results of our study, we also suggest a method to establish a laboratory's own effective cut-off value for S/CO from an anti-HCV assay for oneself.
In conclusion, the new version of the Elecsys Anti-HCV assay showed excellent diagnostic performances, particularly in terms of superior sensitivity, specificity, and NPV. Like other anti-HCV assays, the results by the Elecsys assay showing S/CO less than a certain cut-off would be retested by HCV RNA PCR or another anti-HCV assay, and a clinical laboratory could need to establish its own effective cut-off for S/CO by using the method suggested in this study as an example.
